Direct current cardioversion for symptomatic atrial fibrillation or flutter is feasible and safe in patients implanted with the Watchman left atrial appendage (LAA) occlusion device, even in the ...

A Food and Drug Administration (FDA) advisory committee has voted 11 to 2 against a recommendation that the agency approve a long-studied antiarrhythmic agent for cardioversion of recent-onset atrial ...

A small series provides provocative new data on the safety of performing direct current cardioversion (DCCV) without oral anticoagulation in high-risk patients with a Watchman left atrial appendage ...